[{"data":1,"prerenderedAt":19},["ShallowReactive",2],{"newsroom-feed":3},[4,9,14],{"id":5,"title":6,"href":7,"pubDate":8},"Sumitomo Pharma America Announces Enzomenib (DSP-5336) Receives FDA Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia-2","Sumitomo Pharma America Announces Enzomenib (DSP-5336) Receives FDA Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia","https:\u002F\u002Fnews.us.sumitomo-pharma.com\u002F\u002Fpress-release-details\u002F2026\u002FSumitomo-Pharma-America-Announces-Enzomenib-DSP-5336-Receives-FDA-Orphan-Drug-Designation-for-Treatment-of-Acute-Lymphoblastic-Leukemia\u002Fdefault.aspx","07\u002F30\u002F2026",{"id":10,"title":11,"href":12,"pubDate":13},"Sumitomo Pharma America Earns 2026-2027 Great Place to Work Certification™-1","Sumitomo Pharma America Earns 2026-2027 Great Place to Work Certification™","https:\u002F\u002Fnews.us.sumitomo-pharma.com\u002F\u002Fpress-release-details\u002F2026\u002FSumitomo-Pharma-America-Earns-2026-2027-Great-Place-to-Work-Certification\u002Fdefault.aspx","08\u002F06\u002F2026",{"id":15,"title":16,"href":17,"pubDate":18},"Sumitomo Pharma America Announces First Patient Receives Treatment in Phase 1\u002F2a Study for its Investigational Therapy DSP-3077 for Retinitis Pigmentosa-0","Sumitomo Pharma America Announces First Patient Receives Treatment in Phase 1\u002F2a Study for its Investigational Therapy DSP-3077 for Retinitis Pigmentosa","https:\u002F\u002Fnews.us.sumitomo-pharma.com\u002F\u002Fpress-release-details\u002F2026\u002FSumitomo-Pharma-America-Announces-First-Patient-Receives-Treatment-in-Phase-12a-Study-for-its-Investigational-Therapy-DSP-3077-for-Retinitis-Pigmentosa\u002Fdefault.aspx","08\u002F12\u002F2026",1786713711737]